ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
7 announcements with these filters
Biocon's Pertuzumab biosimilar received a positive CHMP opinion from the EMA, marking a milestone in its European regulatory path. Final European Commission approval is pending.
Biocon secured a 10-year supply contract for Pertuzumab in Brazil under a government program. The partnership involves milestone payments and revenue sharing for the company.
Biocon has initiated the remittance of the final dividend for FY 2025-26. This notification confirms the dispatch process for shareholders.
Mylan Inc. filed a revised SAST disclosure clarifying the sale of 9.19 crore shares in Biocon Limited. The seller's post-disposal holding is now correctly reported as Nil.
Biocon received marketing approval from Japan's MHLW for its Pegfilgrastim biosimilar. This approval enhances Biocon's biosimilar portfolio and market access in Japan.
Biocon's US subsidiary received U.S. FDA approval for the Yesintek® prefilled autoinjector. This supplemental approval enhances the company's immunology portfolio.
Biocon Q1 FY27 revenue grew 10% YoY to INR 3,433 Cr. Biopharmaceuticals grew 17% while Services declined 16%. Group EBITDA was INR 902 Cr (21% margin) and Net Profit jumped 245% to INR 145 Cr.